Strategies for the targeted delivery of therapeutics for osteosarcoma

Expert Opin Drug Deliv. 2009 Dec;6(12):1311-21. doi: 10.1517/17425240903280422.

Abstract

Background: Conventional therapy for osteosarcoma has reached a plateau of 60 - 70%, a 5-year survival rate that has changed little in two decades, highlighting the need for new approaches.

Objective: To review the alternative means of delivering effective therapy for osteosarcoma that reach beyond the central venous catheter.

Methods: Drawing on the author's own experiences providing care to high-risk osteosarcoma patients and reviewing the last two decades of literature describing sarcoma therapy, available information is summarized about potential osteosarcoma treatments that deliver therapy by a less conventional route.

Results/conclusions: Intra-arterial chemotherapy has a limited impact on survival, but may help to achieve a better limb salvage. Intrapleural chemotherapy is important for managing malignant effusions. The development of inhalation therapies, treatments that target new bone formation such as bisphosphonates, chemically targeted radiation and antibody-based therapies all have potential to improve osteosarcoma therapy.

Publication types

  • Review

MeSH terms

  • Animals
  • Antibodies, Monoclonal / immunology
  • Antibodies, Monoclonal / therapeutic use
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / therapeutic use*
  • Bone Neoplasms / drug therapy*
  • Bone Neoplasms / mortality
  • Drug Delivery Systems
  • Humans
  • Limb Salvage / methods
  • Osteosarcoma / drug therapy*
  • Osteosarcoma / mortality
  • Survival Rate

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents